Directors' Dealings

5 February 2024

4basebio plc

(“4babsebio” or the "Company")

Directors’ Dealings

Cambridge, UK, 5 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces that, further to its announcement of 2 February 2024, directors of the Company have sold shares in order to pay for options exercised as follows:

Name Number of Shares Sold Sale price per share (p) Shareholding Following Sale Shareholding as a Percentage of Issued Share Capital
Heikki Lanckriet 45,322 660p 1,418,994 11.09%
David Roth 38,292 660p 457,708 3.58%

The calculations above are based on an issued share capital of the Company of 12,796,208 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

4basebio PLC                +44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson
Cavendish Capital Markets Limited (Broker) +44 (0)20 7220 0500
Geoff Nash/Charlie Beeson
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name
  1. Dr Heikki Lanckriet
  2. David Roth
2 Reason for notification
a. Position/Status
  1. CEO
  2. CFO
b. Initial notification/Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio plc
b. LEI 213800E2DX9EAIUNCB30
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument

Identification Code
Ordinary Shares

b. Nature of the transaction Sale of Ordinary Shares
Price(s) per share (p) Volume(s)
  1. 660p
  2. 660p



d. Aggregated information
  • Volume
  • Price
  • 83,614
  • 660 pence per share
e. Date of the transaction 2/2/2024
f. Place of the transaction London Stock Exchange, AIM


4basebio (4BB)
UK 100

Latest directors dealings